- Home
- FSM vs MIRM Comparison
FSM vs MIRM Comparison
Compare FSM & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSM
- MIRM
- Stock Information
- Founded
- FSM 1990
- MIRM 2018
- Country
- FSM Canada
- MIRM United States
- Employees
- FSM N/A
- MIRM N/A
- Industry
- FSM Precious Metals
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- FSM Basic Materials
- MIRM Health Care
- Exchange
- FSM Nasdaq
- MIRM Nasdaq
- Market Cap
- FSM 2.3B
- MIRM 2.2B
- IPO Year
- FSM N/A
- MIRM 2019
- Fundamental
- Price
- FSM $6.65
- MIRM $50.34
- Analyst Decision
- FSM Hold
- MIRM Strong Buy
- Analyst Count
- FSM 1
- MIRM 12
- Target Price
- FSM $7.00
- MIRM $63.17
- AVG Volume (30 Days)
- FSM 19.0M
- MIRM 397.8K
- Earning Date
- FSM 08-06-2025
- MIRM 08-06-2025
- Dividend Yield
- FSM N/A
- MIRM N/A
- EPS Growth
- FSM N/A
- MIRM N/A
- EPS
- FSM 0.51
- MIRM N/A
- Revenue
- FSM $1,151,277,000.00
- MIRM $379,251,000.00
- Revenue This Year
- FSM N/A
- MIRM $35.83
- Revenue Next Year
- FSM N/A
- MIRM $16.83
- P/E Ratio
- FSM $12.98
- MIRM N/A
- Revenue Growth
- FSM 32.69
- MIRM 69.31
- 52 Week Low
- FSM $3.86
- MIRM $28.56
- 52 Week High
- FSM $7.55
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- FSM 54.46
- MIRM 69.78
- Support Level
- FSM $6.77
- MIRM $48.78
- Resistance Level
- FSM $7.00
- MIRM $50.05
- Average True Range (ATR)
- FSM 0.30
- MIRM 1.64
- MACD
- FSM -0.02
- MIRM 0.39
- Stochastic Oscillator
- FSM 41.61
- MIRM 87.92
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru. The company's segment consists of Mansfield, Sanu, Sango, Cuzcatlan, Bateas, Corporate. The company generates the majority of its revenue from Sango segment which operates the Seguela gold mine. Geographically, the company generates the majority of its revenue from Cote d'Ivoire location.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.